9 completed, 2 terminated, 1 unknown. 12 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 9, Terminated 2, Unknown 1 |
| Phase 2 | 5 | Completed 3, Terminated 1, Unknown 1 |
Follow mavorixafor: new trials by email Literature Review of mavorixafor trials Research Report on mavorixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function Mavorixafor - Hepatic Insufficiency | Phase 1 | Completed | X4 Pharmaceuticals | 39 | 2025-02-28 | 2026-07-15 |
| Drug-Drug Interaction Potential of Mavorixafor Mavorixafor, Carbamazepine, Efavirenz - Healthy Participants | Phase 1 | Completed | X4 Pharmaceuticals | 38 | 2025-02-18 | 2025-07-01 |
| A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders Mavorixafor - Neutropenia | Phase 1 / Phase 2 | Completed | X4 Pharmaceuticals | 32 | 2021-10-16 | 2025-08-06 |
| A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC X4P-001 - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Abbisko Therapeutics Co, Ltd | 24 | 2021-07-21 | 2021-11-02 |
| A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Mavorixafor, Ibrutinib - Waldenstrom's Macroglobulinemia | Phase 1 | Completed | X4 Pharmaceuticals | 16 | 2020-04-30 | 2024-08-27 |
| Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma X4P-001, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | X4 Pharmaceuticals | 9 | 2016-12-07 | 2022-12-29 |
| X4P-001 and Pembrolizumab in Patients With Advanced Melanoma X4P-001, Pembrolizumab - Melanoma | Phase 1 | Completed | X4 Pharmaceuticals | 16 | 2016-09-15 | 2020-07-07 |
| Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma X4P-001, axitinib - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | X4 Pharmaceuticals | 74 | 2016-04-27 | 2024-10-03 |
| A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers X4P-001 - Healthy | Phase 1 | Terminated | X4 Pharmaceuticals | 15 | 2016-01-12 | 2018-12-07 |
| A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus AMD11070 - HIV Infections, X4 Tropic Virus | Phase 1 | Completed | Genzyme, a Sanofi Company | 10 | 2005-10-01 | 2014-02-11 |
| Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients AMD11070 - HIV Infections | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 6 | 2004-11-01 | 2021-11-09 |
| Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men Ritonavir, AMD070 - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 44 | 2021-11-01 |
HIV Infections (3) · Carcinoma, Renal Cell (2) · Glycogen Storage Disease Id (1) · Hepatic Insufficiency (1) · Melanoma (1) · Neutropenia (1) · Triple Negative Breast Neoplasms (1) · Waldenstrom Macroglobulinemia (1)
X4 Pharmaceuticals (8) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Abbisko Therapeutics Co, Ltd (1) · Genzyme, a Sanofi Company (1)
United States (11) · China (1) · Greece (1) · South Korea (1) · United Kingdom (1)
Lu Gan, MD, PhD (2) · Craig Hendrix, MD (1) · J L Zheng, Director (1) · Michael S. Saag, MD (1)
PMID 17452489, PMID 18285477, PMID 19193109, PMID 33507454, PMID 36923305
2019 (1)